Gene-environment interactions in the pathogenesis of type 2 diabetes and metabolism

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 10, Issue 4, 2007, Pages 420-426

  Grarup, Niels ^a   Andersen, Gitte ^a  

^a STENO DIABETES CENTER   (Denmark)

Author keywords

Behaviour; Diet; Genetics; Lifestyle; Lipid; Obesity

Indexed keywords

APOLIPOPROTEIN A5; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN; TRANSCRIPTION FACTOR 7 LIKE 2; UNCLASSIFIED DRUG;

DIET; ENVIRONMENTAL FACTOR; GENE INTERACTION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HUMAN; LIFESTYLE; METABOLISM; MULTIFACTORIAL GENETIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION; OBESITY; OUTCOME ASSESSMENT; PATHOGENESIS; PHENOTYPE; PHYSICAL ACTIVITY; PROMOTER REGION; REVIEW; RISK ASSESSMENT;

DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; ENVIRONMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIFE STYLE; LIPID METABOLISM; NUTRITION PHYSIOLOGY; OBESITY; POLYMORPHISM, GENETIC;

EID: 34250616639     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e3281e2c9ab     Document Type: Review

References (60)

1. Katan MB, Beynen AC, De Vries JH, Nobels A. Existence of consistent hyporesponders and hyperresponders to dietary cholesterol in man. Am J Epidemiol 1986; 123:221-234.
2. Loktionov A. Common gene polymorphisms and nutrition: emerging links with pathogenesis of multifactorial chronic diseases. J Nutr Biochem 2003; 14:426-451.
3. Sampath H, Ntambi JM. Polyunsaturated fatty acid regulation of genes of lipid metabolism. Annu Rev Nutr 2005; 25:317-340.
4. Avery CL, Freedman BI, Kraja AT, et al. Genotype-by-sex interaction in the aetiology of type 2 diabetes mellitus: support for a sex-specific quantitative trait loci in Hypertension Genetic Epidemiology Network participants. Diabetologia 2006; 49:2329-2336.
5. North KE, Franceschini N, Borecki IB, et al. Genotype-by-sex interaction on fasting insulin concentration. The HyperGEN Study. Diabetes 2007; 56:137-142.
6. 2, a marker of inflammation and oxidative stress. Am J Hum Genet 2007; 80:168-177.
7. Wareham NJ, Franks PW, Harding A-H. Establishing the role of geneenvironment interactions in the etiology of type 2 diabetes. Endocrinol Metab Clin North Am 2002; 31:553-566.
8. Smith PG, Day NE. The design of case-control studies: the influence of confounding and interaction effects. Int J Epidemiol 1984; 13:356-365.
9. Andersen G, Hansen T, Pedersen O. Genetics of common forms of glycaemia with pathological impact on vascular biology: are we on the right track? Curr Mol Med 2005; 5:261-274.
10. DECODE Study Group. European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003; 26:688-696.
11. Khaw K-T, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 2001; 322:1-6.
12. Thuren T. Hepatic lipase and HDL metabolism. Curr Opin Lipidol 2000; 11:277-283.
13. Lambert G, Chase MB, Dugi K, et al. Hepatic lipase promotes the selective uptake of high density lipoprotein-cholesteryl esters via the scavenger receptor B1. J Lipid Res 1999; 40:1294-1303.
14. Tahvanainen E, Syvanne M, Frick MH, et al. Association of variation in hepatic lipase activity with promoter variation in the hepatic lipase gene. The LOCAT Study Investigators. J Clin Invest 1998; 101:956-960.
15. Isaacs A, Sayed-Tabatabaei FA, Njajou OT, et al. The -514 C->T hepatic lipase promoter region polymorphism and plasma lipids: a meta-analysis. J Clin Endocrinol Metab 2004; 89:3858-3863.
16. Corella D, Ordovas JM. Single nucleotide polymorphisms that influence lipid metabolism: interaction with dietary factors. Ann Rev Nutr 2005; 25:341-390.
17. Franks PW, Mesa J-L, Harding AH, Wareham NJ. Gene-lifestyle interaction on risk of type 2 diabetes. Nutr Metab Cardiovasc Dis 2007; 17:104-124. A thorough literature survey of published gene-lifestyle interaction studies up to 2005. Gives a brief overview of studies of selected genes and includes meticulous tables of published studies.
18. Ordovas JM, Corella D, Demissie S, et al. Dietary fat intake determines the effect of a common polymorphismin the hepatic lipase gene promoter on high-density lipoprotein metabolism: evidence of a strong dose effect in this gene-nutrient interaction in the Framingham Study. Circulation 2002; 106:2315-2321.
19. Tai ES, Corella D, Deurenberg-Yap M, et al. Dietary fat interacts with the -514C>T polymorphism in the hepatic lipase gene promoter on plasma lipid profiles in a multiethnic Asian population: the 1998 Singapore National Health Survey. J Nutr 2003; 133:3399-3408.
20. Zhang C, Lopez-Ridaura R, Rimm EB, et al. Interactions between the -514C->T polymorphism of the hepatic lipase gene and lifestyle factors in relation to HDL concentrations among US diabetic men. Am J Clin Nutr 2005; 81:1429-1435.
21. Nettleton JA, Steffen LM, Ballantyne CM, et al. Associations between HDL-cholesterol and polymorphisms in hepatic lipase and lipoprotein lipase genes are modified by dietary fat intake in African American and White adults. Atherosclerosis 2006; [Epub ahead of print] A report of an interesting investigation of the relationship between variation in LIPC and dietary factors in a large-scale sample of around 12 000 subjects.
22. Teran-Garcia M, Santoro N, Rankinen T, et al. Hepatic lipase gene variant -514C>T is associated with lipoprotein and insulin sensitivity response to regular exercise: the HERITAGE Family Study. Diabetes 2005; 54:2251-2255.
23. Hokanson JE, Kamboh MI, Scarboro S, et al. Effects of the hepatic lipase gene and physical activity on coronary heart disease risk. Am J Epidemiol 2003; 158:836-843.
24. Todorova B, Kubaszek A, Pihlajamäki J, et al. The G-250A promoter polymorphism of the hepatic lipase gene predicts the conversion from impaired glucose tolerance to type 2 diabetes mellitus: the Finnish Diabetes Prevention Study. J Clin Endocrinol Metab 2004; 89:2019-2023.
25. Zacharova J, Todorova BR, Chiasson JL, Laakso M. The G-250A substitution in the promoter region of the hepatic lipase gene is associated with the conversion from impaired glucose tolerance to type 2 diabetes: The STOP-NIDDM trial. J Int Med 2005; 257:185-193.
26. Jakel H, Nowak M, Helleboid-Chapman A, et al. Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins? Ann Med 2006; 38:2-10. A comprehensive review of the literature supporting a role of apolipoprotein A5 in lipid metabolism with main focus on genetic studies.
27. Pennacchio LA, Olivier M, Hubacek JA, et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001; 294:169-173.
28. Grosskopf I, Baroukh N, Lee S-J, et al. Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceriderich lipoproteins and removal of their remnants. Arterioscler Thromb Vasc Biol 2005; 25:2573-2579.
29. van der Vliet HN, Schaap FG, Levels JHM, et al. Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem Biophys Res Commun 2002; 295:1156-1159.
30. Fruchart-Najib J, Bauge E, Niculescu L-S, et al. Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem Biophys Res Commun 2004; 319:397-404.
31. Schaap FG, Rensen PCN, Voshol PJ, et al. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem2004; 279:27941-27947.
32. Merkel M, Loeffler B, Kluger M, et al. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem 2005; 280:21553-21560.
33. Martin S, Nicaud V, Humphries SE, Talmud PJ. Contribution of APOA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges. Biochim Biophys Acta 2003; 1637:217-225.
34. Jang Y, Kim JY, Kim OY, et al. The -1131T→C polymorphism in the apolipoprotein A5 gene is associated with postprandial hypertriacylglycerolemia; elevated small, dense LDL concentrations; and oxidative stress in nonobese Korean men. Am J Clin Nutr 2004; 80:832-840.
35. Aberle J, Evans D, Beil FU, Seedorf U. A polymorphism in the apolipoprotein A5 gene is associated with weight loss after short-term diet. Clin Genet 2005; 68:152-154.
36. Lai C-Q, Corella D, Demissie S, et al. Dietary intake of n-6 fatty acids modulates effect of apolipoprotein A5 gene on plasma fasting triglycerides, remnant lipoprotein concentrations, and lipoprotein particle size. The Framingham Heart Study. Circulation 2006; 113:2062-2070. A large-scale study showing significant interaction between dietary polyunsaturated fatty acids and APOA5 polymorphisms on fasting triglyceride levels, remnant-like particle concentrations, and lipoprotein particle size, especially for n-6 fatty acids.
37. Andersen G, Sparsø T, Albrechtsen A, et al. Modulation of genetic susceptibility by behavioral factors and glucose regulation status in the general population exemplified by the impact of the APOA5 -1131T>C variant on serum lipids. Diabetologia 2006; 49 (S):163.
38. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997; 99:2416-2422.
39. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 1994; 79:1147-1156.
40. Motojima K, Passilly P, Peters JM, et al. Expression of putative FA transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. J Biol Chem 1998; 273:16710-16714.
41. Semple RK, Chatterjee VKK, O'Rahilly S. PPARγ and human metabolic disease. J Clin Invest 2006; 116:581-589. An excellent and updated review of the role of PPARγ in metabolic disease.
42. Barroso I, Gurnell M, Crowley VE, et al. Dominant negative mutations in human PPARg associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402:880-883.
43. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26:76-80.
44. Beamer BA, Yen CJ, Andersen RE, et al. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-γ2 gene with obesity in two Caucasian populations. Diabetes 1998; 47:1806-1808.
45. Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20:284-287.
46. Ek J, Andersen G, Urhammer SA, et al. Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 (PPAR-γ2) gene in relation to insulin sensitivity among glucose tolerant caucasians. Diabetologia 2001; 44:1170-1176.
47. Soriguer F, Morcillo S, Cardona F, et al. Pro12Ala polymorphismof the PPARG2 gene is associated with type 2 diabetes mellitus and peripheral insulin sensitivity in a population with a high intake of oleic acid. J Nutr 2006; 136:2325-2330. A population-based study that examines the association of PPARG Pro12Ala genotype with insulin resistance and glucose intolerance in the context of gene-diet interaction in a Mediterranean cohort.
48. Brand-Herrmann S-M, Kuznetsova T, Wiechert A, et al. Alcohol intake modulates the genetic association between HDL cholesterol and the PPARγ2 Pro12Ala polymorphism. J Lipid Res 2005; 46:913-919.
49. Adamo KB, Sigal RJ, Williams K, et al. Influence of Pro12Ala peroxisome proliferator-activated receptor gamma2 polymorphism on glucose response to exercise training in type 2 diabetes. Diabetologia 2005; 48:1503-1509.
50. Weiss EP, Kulaputana O, Ghiu IA, et al. Endurance training-induced changes in the insulin response to oral glucose are associated with the peroxisome proliferator-activated receptor-γ2 Pro12Ala genotype in men but not in women. Metabolism 2005; 54:97-102.
51. Lindi VI, Uusitupa MI, Lindstrom J, et al. Association of the Pro12Ala polymorphism in the PPAR-γ2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes 2002; 51:2581-2586.
52. Florez JC, Jablonski AK, Sun MW. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab 2007; 92:1502-1509. A large-scale intervention study of type 2 diabetes including more than 3500 participants with impaired glucose tolerance. No interaction of PPARG Pro12Ala genotype with lifestyle intervention or medical treatment on progression to type 2 diabetes is observed.
53. de Rooij SR, Painter RC, Phillips DI, et al. Impaired insulin secretion after prenatal exposure to the Dutch famine. Diabetes Care 2006; 29:1052-1057. A most interesting study of a unique birth cohort exposed to prenatal famine during World War II. The paper shows that the effect of PPARG Pro12Ala genotype on type 2 diabetes and insulin secretion is modulated by prenatal exposure to famine during mid-gestation.
54. Eriksson J, Lindi V, Uusitopa M, et al. The effects of the Pro12Ala polymorphism of the PPARγ-2 gene on lipid metabolism interact with body size at birth. Clin Genet 2003; 64:366-370.
55. Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006; 38:320-323. The original paper from deCODE genetics describing the observation of TCF7L2 as a type 2 diabetes susceptibility gene. Includes independent replication of significant findings.
56. Groves CJ, Zeggini E, Minton J, et al. Association analysis of 6 736 U. K. subjects provides replication and confirms TCF7L2 as a type 2 diabetes susceptibility gene with a substantial effect on individual risk. Diabetes 2006; 55:2640-2644.
57. Helgason A, Palsson S, Thorleifsson G, et al. Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet 2007; 39:218-225. An interesting study refining the association of variation in TCF7L2 with type 2 diabetes.
58. Florez JC, Jablonski AK, Bayley N, et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl JMed 2006; 355:241-250. A large-scale intervention study of type 2 diabetes including more than 3500 participants with impaired glucose tolerance. Describes the relationship between lifestyle intervention, TCF7L2 genotypes and progression to type 2 diabetes.
59. Wong MY, Day NE, Luan JA, et al. The detection of gene-environment interaction for continuous traits: should we deal with measurement error by bigger studies or better measurement? Int J Epidemiol 2003; 32:51-57.
60. Albrechstein A, Castella S, Andersen G, et al. Bayesian multi-loci association method: allowing for higher-order interaction in association studies. Genetics 2007 [E-pub ahead of print].